Peficitinib
Clinical data | |
---|---|
Trade names | Smyraf |
Other names | ASP015K; JNJ-54781532 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
JSmol) | |
| |
|
Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).[1][2]
Peficitinib was approved for use in Japan in 2019.[3]